Diabetic Kidney Disease: Act Now or Pay Later

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2009 Dec 17

PMID 20012995

Authors

Robert C Atkins

Paul Zimmet

Affiliations

Soon will be listed here.

References

Parving H, Lewis J, Ravid M, Remuzzi G, Hunsicker L . Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006; 69(11):2057-63. DOI: 10.1038/sj.ki.5000377. View

Ninomiya T, Perkovic V, de Galan B, Zoungas S, Pillai A, Jardine M . Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009; 20(8):1813-21. PMC: 2723977. DOI: 10.1681/ASN.2008121270. View

Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851-60. DOI: 10.1056/NEJMoa011303. View

Burney B, Kalaitzidis R, Bakris G . Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2009; 18(2):107-11. DOI: 10.1097/MNH.0b013e3283249c51. View

Whaley-Connell A, Sowers J, McCullough P, Roberts T, McFarlane S, Chen S . Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009; 53(4 Suppl 4):S11-21. DOI: 10.1053/j.ajkd.2009.01.004. View

Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12):870-8. DOI: 10.1056/NEJMoa011489. View

Zoungas S, de Galan B, Ninomiya T, Grobbee D, Hamet P, Heller S . Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009; 32(11):2068-74. PMC: 2768202. DOI: 10.2337/dc09-0959. View

Yoon K, Lee J, Kim J, Cho J, Choi Y, Ko S . Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006; 368(9548):1681-8. DOI: 10.1016/S0140-6736(06)69703-1. View

Ruggenenti P, Fassi A, Ilieva A, Bruno S, Iliev I, Brusegan V . Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004; 351(19):1941-51. DOI: 10.1056/NEJMoa042167. View

10.

Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S . Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008; 12(1):1-8. DOI: 10.1007/s10157-007-0010-9. View

11.

Patel A, Macmahon S, Chalmers J, Neal B, Woodward M, Billot L . Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590):829-40. DOI: 10.1016/S0140-6736(07)61303-8. View

12.

Dunstan D, Zimmet P, Welborn T, de Courten M, Cameron A, Sicree R . The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002; 25(5):829-34. DOI: 10.2337/diacare.25.5.829. View

13.

Thomas M, Viberti G, Groop P . Screening for chronic kidney disease in patients with diabetes: are we missing the point?. Nat Clin Pract Nephrol. 2007; 4(1):2-3. DOI: 10.1038/ncpneph0679. View

14.

White S, Polkinghorne K, Cass A, Shaw J, Atkins R, Chadban S . Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust. 2008; 188(4):204-8. DOI: 10.5694/j.1326-5377.2008.tb01585.x. View

15.

King H, Aubert R, Herman W . Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21(9):1414-31. DOI: 10.2337/diacare.21.9.1414. View

16.

Zimmet P, Alberti K, Shaw J . Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782-7. DOI: 10.1038/414782a. View

17.

Lysaght M . Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002; 13 Suppl 1:S37-40. View

18.

Adler A, Stevens R, Manley S, Bilous R, Cull C, Holman R . Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2002; 63(1):225-32. DOI: 10.1046/j.1523-1755.2003.00712.x. View

19.

Bilous R . Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?. Diabet Med. 2008; 25 Suppl 2:25-9. DOI: 10.1111/j.1464-5491.2008.02496.x. View

20.

Gaede P, Lund-Andersen H, Parving H, Pedersen O . Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358(6):580-91. DOI: 10.1056/NEJMoa0706245. View